The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Abstract

Background In addition to 4 CRAB criteria, 3 biomarkers were adopted as myeloma-defining events: clonal marrow plasma cell (PC) percentage ≥60%, serum free light chain ratio (SFLCR) ≥100 and >1 MRI focal lesion, known as SLiM (SixtyLightchainMRI), but there has been no analysis of their clinical impact. Methods We compared the characteristics, treatment & outcomes of 1686 pts diagnosed by CRAB and 132 pts by SLiM enrolled in the MRDR from 2013 - 2018, to assess the impact of these criteria on clinical practice and treatment outcomes. Results Patient & Disease characteristics. In 132 SLiM pts, 48 had SFLCR≥100, 58 BMPC>60% and 26 were known to have both, nil had MRI lesions (limited by MRI av..